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abstract
Sarcoidosis is a granulomatous condition, primarily affecting the lungs and thoracic 
lymph nodes. Clinical cardiac involvement might occur in 2 to 5% of patients with 
sarcoidosis, and can be associated with serious complications including heart block, 
cardiomyopathy, ventricular arrhythmias, and potentially death. Timely diagnosis helps 
initiate treatment before cardiac damage becomes irreversible. In this brief review, we 
discuss imaging updates for diagnosis and monitoring of cardiac sarcoidosis.
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Sarcoidosis is a chronic granulomatous disorder. Although 
primarily affecting the lungs and thoracic lymph nodes, clin-
ically it involves the heart in up to 5% of patients causing se-
rious morbidity and mortality.[1, 2] Autopsy data suggest 
cardiac involvements in up to 25%, emphasizing that there 
may be an underestimation due to the difficulty in diagnosis.
[3, 4] Signs and symptoms depend on the site and extent of 
cardiac involvement, and include conduction abnormalities, 
and heart failure.[5] The diagnosis is usually made by existing 
recommendations, including those from the Japanese Min-
istry of Health and Welfare Criteria for Diagnosis of Cardiac 
Sarcoidosis (Revised 2006) and Heart Rhythm Society Ex-
pert Consensus Statement.[6, 7] Timely diagnosis can help 
direct specific treatments to ameliorate the disease course and 
avoid unnecessary interventions. Suggestive findings include 
increased myocardial wall thickness, regional wall motion ab-
normalities, systolic or diastolic dysfunction, and pericardial 
effusions on transthoracic echocardiography.[8] However, 
transthoracic echocardiography is not, in isolation, diagnostic 
for cardiac sarcoidosis. Historically, the diagnosis was made 
by endomyocardial biopsy. However, cardiac involvement 
could be patchy and missed by a single biopsy. Multiple biop-
sies are not feasible because of the increased procedural risks, 
and long-term complications such as tricuspid regurgitation.
[9, 10] Use of cardiac magnetic resonance (CMR) imaging, 
and positron emission tomography (PET) have redefined the 
timeliness of diagnosis, and have provided avenues for moni-
toring the response to treatment. Here we briefly review these 
imaging advances in diagnosis and monitoring of sarcoidosis.
Diagnosis
Endomyocardial biopsy is the gold standard diagnostic meth-
od. However, focal involvement of the heart is one the limita-
tions of biopsies. Increasing the sensitivity of biopsy by sam-
pling multiple sites increases procedural risk. Thus, diagnostic 
utility of endomyocardial biopsy is limited. CMR imaging can 
evaluate the entire myocardium for sarcoid involvement and 
also evaluates cardiac structure, perfusion, and function.[11] 
CMR can show wall thickness abnormalities, edema, patchy 
involvement, and chronic fibrotic scar with delayed gadolin-
ium enhancement.[8, 12] T1-weighted images can demon-
strate structural changes and T2-weighted images can detect 
the acute phase of inflammation.[13] Cine MR sequences 
assess wall motion abnormalities (hypokinesia or akinesia) 
due to scar or inflamation.[14] In the appropriate clinical con-
text, the diagnosis of sarcoidosis is based upon the presence 
of patchy, subepicardial late gadolinium enhancement (LGE), 
which identifies fibrosis, or advanced disease.[14] MRI can 
also provide information about the mediastinum and possible 
Mehdipoor, et al
22
International Journal of Cardiovascular Practice 
extracardiac signs. Cardiac sarcoidosis without known or ap-
parent extracardiac sarcoidosis has been reported previously, 
but is relatively rare.[15-18] Fluid sensitive sequences can also 
provide valuable information about the myocardial edema at 
earlier stages, but the role in the diagnosis of cardiac sarcoidosis 
is not clear.[7, 19] Since diagnosing sarcoidosis required gad-
olinium (typically a double dose), limitations include a risk of 
nephrogenic systemic fibrosis when GFR < 30 ml/min as well 
as allergic reactions to the gadolinium-based contrast agents.
[20, 21] PET imaging is also commonly used to assess active 
cardiac sarcoidosis (Table 1).
PET requires a special patient dietary preparation to re-
duce glucose uptake by normal myocardium.[5] The pa-
tient must have a high protein, high fat, low carbohydrate 
diet for 24 hours prior to PET scanning. This reduces the 
glucose uptake by myocytes. Alternatively, unfractionat-
ed heparin could be administered to increase fatty acid 
availability. Upon arrival in nuclear cardiology laboratory, 
a rest N13 labeled ammonia PET is performed to identify 
myocardial perfusion defects. Then in the same setting 
F-18 Fluorodeoxyglucose (FDG) can be administered to 
identify sites of myocardial inflammation[22] as well as 
lymph nodes in the active phase of disease. Cardiac PET 
images are classified based on the perfusion defect and the 
corresponding FDG uptake into four categories of normal, 
early disease, progressive disease, and fibrous disease.[9, 
23] The ability of FDG PET scan to identify inflammation 
can detect the disease at earlier stages, which is import-
ant for treatment before fibrosis happens.[9] Whole-body 
PET may be useful for detecting extracardiac involve-
ment, especially in cases initially presenting with isolated 
cardiac sarcodosis.[17] 
FDG PET can discover active cardiac sarcoidosis and is 
considered more sensitive than other radionuclide imaging 
tests. It assesses the hypermetabolic activity of myocardi-
um due to inflammation. The most important advantage 
of FDG PET over MRI, is more accurate quantification of 
myocardial FDG uptake in sarcoidosis, which can assess 
response to therapy.[9] FDG is not accumulated in normal 
vascular structures. Neoplastic PET uptake could be dif-
ferentiated since the uptake is more intense than other in-
flammatory diseases (including sarcoidosis).[24] On PET/ 
computed tomography (CT), the manifestations may in-
clude patchy or diffuse hypermetabolic activity. Cross-sec-
tional imaging studies are complementary for precise lo-
calization of anatomic involvement.[24] FDG PET is also 
a useful imaging tool for diagnosis, evaluating disease ac-
tivity, and monitoring the response to treatment in patients 
with sarcoidosis.[9] PET/ CT scan using F-18 sodium flu-
oride has been tested in recent years but does not appear to 
detect myocardial inflammation caused by suspected car-
diac sarcoidosis.[25] Nuclear imaging tests for diagnosis 
of cardiac sarcoidosis are generally performed with thalli-
um, technetium pyrophosphate, and gallium. Coronary ar-
tery disease should be differentiated from cardiac sarcoid-
osis by further pharmacological assessment usually with 
dipyridamole. Perfusion-inflammation mismatch happens 
in cardiac sarcoidosis. Alternatively, in those with newly 
discovered cardiomyopathy, coronary disease might be 
interrogated by other modalities, including cardiac cath-
eterization. Gallium is sensitive for cardiac sarcoidosis. 
However, the currently available gallium scans are not 
sufficiently clear to differentiate between mediastinal and 
lung disease versus cardiac involvement with sarcoidosis.
[26] A combined approach using FDG PET and CMR 
can assess inflammation, scar, fibrosis and wall motion 
abnormalities. Combined imaging modalities may help 
in confirmation of the diagnosis with higher confidence, 
better tissue characterization, and prognostication. Re-
cently, guided biopsy with CMR or PET has been shown 
to be helpful. However, a negative biopsy does not ex-
clude the diagnosis.[8] Real-time MRI guided biopsy has 
been reported to provide a better tissue characterization 
for guided biopsy from the patchy involvements.[27, 28] 






 -Performed at beside with
cardiac ultrasound probes
 -Needs a special dietary preparation
in advance, with or without admin-
istration of intravenous unfraction-
 ated heparin. Imaging is done after
about 90 minutes of FDG uptake.
 Cine short axis, 4-chamber and 3-chamber views;
 Gadolinium to assess patchy and late enhancement as
well as T1 and T2 weighted images.
 Role in diagnosis/
 prognosis / follow
up




-A sensitive tool to assess the hyper-
 metabolic activity of myocardium
due to inflammation
-Can identify patchy and Late gadolinium enhance-
 ment in diagnosis of fibrosis -T1-weighted images are
useful for assessing structural changes and T2-weight-
 ed images for acute phases of inflammation and
edema
 Strengths  -Relatively inexpensive,
 readily available, no
adverse effects
 -No immediate complications
 -helpful to assess extracardiac
disease -A quantitative tool for as-
sessment of response-to-treatment
 -Can identify other cardiomyopathies or infiltrative
diseases with similar presentations - No ionizing radi-
ation -Prognostic utility -Provides valuable informa-
tion about the lungs and thoracic lymph nodes
limitations  -Insufficient for definite
diagnosis
-Radiation  -Some patients may have intracardiac devices that
 are known to be incompatible with MRI -Length
 of imaging is long for patients -Risk of nephrogenic
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Figure 1: Flow Diagram for Diagnostic Evaluation for Suspected Cardiac Sarcoidosis
We should reemphasize that in patients with suggestive 
history and related cardiac findings, diagnosis of sarcoid-
osis should be considered once other common causes of 
cardiomyopathy, such as coronary disease, have been ex-
cluded and then an imaging modality would help for mak-
ing the diagnosis (Fig 1).
Prognostic Significance
Initial echocardiographic assessment is helpful in prog-
nostication and has been reported in a number of patients 
who are not responsive to immunosuppression therapy.
[5, 15, 29] In CMR, late gadolinium enhancement has 
also been reported to be an important prognostic factor 
and is associated with sudden cardiac death, implantable 
cardioverter-defibrillator (ICD) discharge, and ventricu-
lar arrhythmias in patients with systemic sarcoidosis.[2, 
5, 8, 29-31] In addition, in a prospective study of car-
diac sarcoidosis in 118 patients, FDG PET abnormality 
was associated with sudden cardiac death or ventricular 
tachycardia.[23] Clinically overt heart failure and im-
paired LV function portends dismal outcomes.[15] 
Monitoring Disease activity
PET imaging is an option to monitor the response to 
immunosuppressive therapy.[32] Serial FDG-PET can 
show normalization of tissue uptake after treatment 
which is also associated with improved outcomes, or 
may show cases resistant to treatment that might require 
adjusting therapies.[33, 34] The data about the follow-up 
of patients with CMR, is probably limited due to incom-
patibility of intracardiac devices such as defibrillators, 
commonly recommended for these patients, and MRI. 
However, in a recent study assessing the safety of MRI 
in 1509 patients with pacemakers or implantable cardio-
verter defibrillator, no long term clinically significant 
adverse events were reported.[35] Therefore, it is like-
ly that future studies can assess the potential impact of 
CMR on response to therapy, as well. 
CONCluSIONS
Cardiac sarcoidosis is a debilitating inflammatory cardi-
ac myopathy that can lead into adverse outcomes includ-
ing death. Although endomyocardial biopsy is the gold 
standard for diagnosis, existing and growing evidence 
and consensus statements[1] suggest that an algorithm 
of careful evaluation based on symptoms, signs, basic 
tests (such as electrocardiogram and echocardiogram) 
and advanced imaging modalities (such as CMR and 
FDG PET) can help make the diagnosis in most suspect-
ed patients. CMR and FDG-PET are complementary and 
provide valuable information for diagnosis and follow 
up. Hybrid imaging with PET-MR is a novel method to 
evaluate cardiac sarcoidosis and may improve the yield 
and timeliness of diagnosis.[36] Endomyocardial biopsy 
would be considered in selected cases, including those 
with inconclusive non-invasive test results, or those with 
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